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Purpose: Recanalization after acute lower limb deep venous thrombosis (DVT) is well 
documented, but the precise mechanism and timing of these events has not been well 
characterized. Regression of DVT has been presumed to result from activation of the 
endogenous fibrinolytic system. This study was performed to compare measurements of 
the enzymatic components of the intrinsic fibrinolytic system (tissue plasrninogen activa- 
tor [tPA], plasminogen activator inhibitor [PAI-1]) with the observed morphologic 
changes in thrombosed venous segments using venous duplex ultrasotmd scanning 
(VDUS) at intervals after diagnosis of acute DVT. 
Methods: Nineteen patients with acute DVT tmderwent serial VDUS to assess regression 
ofthrombus at intervals of I to 2 weeks, 3 to 6 weeks, 8 to 12 weeks, and 24 to 36 weeks. 
The extent of thrombus in each limb was quantitated at each interval by VDUS of the 
residual thrombus present in each of five major axial venous segments: the common 
femoral, superficial femoral, profunda femoris, popliteal, and tibial veins. Thrombus 
scores for the group at each interval were compared with baseline scores at diagnosis to 
calculate the percent residual thrombus. Endogenous fibrinolytic activity was determined 
at the same intervals byserologic assay of the biologic activities of tPA and its inhibitor 
PAI-1. 
Results: Thrombus regression was evident by VDUS at 1 to 2 weeks and progressed such 
that only 26% of residual thrombus remained at 24 to 36 weeks. Complete resolution of 
thrombus occurred in 10 of 18 patients (56%) who completed the 9-month study. 
Baseline mean tPA activity was 0.60 + 0.07 IU/ml  and increased to 1.31 + 0.26 IU /ml  
at i to 2 weeks (p = 0.014). tPA activity remained significantly elevated through the 8 to 
12 week interval and returned to baseline at 24 to 36 weeks. PAI-1 activity was elevated 
relative to an age-matched population at baseline (23.1 -+ 1.8 AU/ml) but remained 
unchanged throughout the study period. Progression of thrombus was observed in three 
patients (15.8%). Patients who experienced propagation of thrombus did not have the 
increased tPA activity that appeared to mark activation of intrinsic fibrinolysis. 
Conclusions: Regression of acute DVT begins early and continues for at least 9 months. It 
is accompanied by significant enhancement of the endogenous fibrinolysis, which appears 
to be primarily mediated by increased tPA activity. Patients who have thrombus propa- 
gation in spite of standard antithrombotic therapy may have failure of activation of 
endogenous fibrinolysis. (J Vasc Surg 1997;26:861-8.) 
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Deep venous thrombosis (DVT) is a common 
ailment. Techniques for diagnosis of DVT and regi- 
mens for its therapy have been a standard part of 
medical care for more than a century. However, the 
natural history of DVT &~ring and after medical 
treatment has been less well documented. Early stud- 
ies suggested that recanalization of thrombosed ve- 
nous segments occurred in as many as 70% of affected 
limbs but was a relatively late phenomenon, being 
seen at periods of 6 months to many ears after acute 
DVT? ,2 Past studies required phlebography and 
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were performed on small numbers of patients. Non- 
invasive vascular testing techniques have made serial 
examinations possible without risk or discomfort for 
the patients. Venous duplex ultrasound scanning 
(VDUS) allows direct imaging of major venous eg- 
ments and has become the primary diagnostic tech- 
nique for the initial evaluation of patients with DVT. 
The accuracy of VDUS for imaging proximal DVT 
has been essentially equal to that of contrast venog- 
raphy, 3 and it was logical to use this technique to 
evaluate the natural history of DVT. Preliminary 
studies of the natural history of acute DVT using 
VDUS have reported that lysis begins early after 
thrombus formation and continues through at least 
the first 6 months. 46 These studies have observed 
that 75% ofthrombosed lower extremity venous eg- 
ments will show some evidence of recanalization, 4 
and as many as 50% of cases of DVT will undergo 
complete resolution within 6 months. 5,6 Studies us- 
ing VDUS have also demonstrated that propagation 
of DVT, rather than clot lysis, may occur in 20% to 
40% of patients despite adequate anticoagulant ther- 
apy.6, 7
The resolution, "recanalization," or "lysis" of 
lower extremity DVT has been assumed to be a result 
of enhanced activity of the endogenous fibrinolytic 
system because standard antithrombotic therapy 
with heparin and warfarin has no proven fibrinolytic 
activity. However, the specific mechanism of endog- 
enous lysis of DVT has not previously been well 
characterized. Endogenous fibrinolytic activity is at 
present best reflected by the balance between the 
biologic activities of tissue plasminogen activator 
(tPA) and its naturally occurring inhibitor, plas- 
minogen activator inhibitor (PAl- 1).8 Enzymatic 
cleavage ofplasminogen b~( tPA results in the gen- 
eration of the active enzyme plasmin, which lyses 
fibrin clots; tPA is inactivated by formation of a 
complex with PAI-1. The present study was per- 
formed to characterize changes in the endogenous 
fibrinolytic activity in patients after acute DVT by 
serial measurement of the in vivo biologic activities 
of tPA and PAI-1. Changes in systemic endoge- 
nous fibrinolytic activity measured in patients with 
acute lower extremity DVT were compared with 
the morphologic changes (lysis or propagation) 
observed in the thrombosed venous segments us- 
ing serial VDUS. An attempt was made to correlate 
the observed extent of clot lysis with the biologic 
activation of endogenous fibrinolytic activity and 
to more precisely identify the enzymatic mecha- 
nism of these changes. An attempt was also made 
to correlate both the biologic and morphologic 
findings with the clinical outcome in the study 
patients. 
PATIENTS AND METHODS 
The study group consisted of 19 men who were 
patients at the Baltimore Veterans Affairs Medical 
Center. These patients had a mean age of 52 years, 
and all had acute lower extremity DVT diagnosed by 
VDUS. All patients in this study had proximal DVT, 
and all DVT in the study group was unilateral. Some 
patients had associated calf vein thromboses (as 
noted below), but patients with isolated calf vein 
DVT were not studied. Patients with iliac or iliocaval 
DVT were not studied because of the relative lack of 
standardization of VDUS in these anatomic areas. 
The risk factors for DVT in the study group included 
malignancy (three patients), recent surgical proce- 
dure (two patients), paraplegia (two patients), pro- 
longed immobility (three patients), history of previ- 
ous DVT (four patients), nephrotic syndrome (one 
patient), and congestive heart failure (two patients). 
In two patients no obvious risk factors could be 
identified. 
The new onset of unilateral limb edema led to 
initial VDUS examination i  13 of the 19 patients 
(68%). In two patients, unilateral leg pain suggested 
the diagnosis of DVT and led to VDUS diagnosis. 
Acute pulmonary embolism led to a secondary diag- 
nosis of DVT in four patients (21%), and three of 
these patients also had lower extremity edema t the 
time of initial evaluation. Overall, clinically signifi- 
cant limb edema was present at the time of diagnosis 
in 16 of 19 patients (84%). 
All patients in this study who had acute DVT 
were treated with anticoagulant therapy that con- 
sisted of continuous intravenous unfractionated hep- 
arin followed by oral sodium warfarin. Heparin treat- 
ment was begun at the time of diagnosis and was 
continued until warfarin therapy resulted in an inter- 
national normalized ratio of 2.0 or greater (mean 
duration of heparin therapy, 5 days). Systemic anti- 
coagulant therapy was continued in all patients for at 
least 6 months. One patient died during the study 
period as a result of complications of a malignancy, 
but there were no cases of pulmonary embolism after 
the initiation of anticoagulant therapy in this study 
group. 
Extent of DVT. The initial diagnosis and classi- 
fication of the extent of DVT was established in each 
patient using VDUS with a commercially available 
color-flow duplex ultrasound unit (HDI UM-9, Ad- 
vanced Technology Laboratories, Bothell, Wash.). 
The technique of VDUS and the diagnostic riteria 
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Table I. Extent of initial lower extremity 
DVT 
Involved venous egments No. of patients 
Common femoral, superficial femoral, and popliteal 3 
Common femoral and superficial femoral 1 
Common femoral 1 
Superficial femoral and popliteal 4 
Superificial femoral, popliteal, and tibial 1 
Superifical femoral 5 
Popliteal and tibial 1 
Popliteal 3 
Total 19 
for acute DVT have been described previously? Du- 
plex scan assessment of five specific anatomic venous 
segments was performed in each patient, including 
the common femoral vein, the superficial femoral 
vein, the profunda femoris vein, the popliteal vein, 
and the tibial veins. The quantitative xtent of 
thrombosis n each limb studied by VDUS was calcu- 
lated based on the system of Porter et al.9 using a 
score assigned to each involved venous segment as 
follows: 0, patent; 1, subsegmental nonocclusive 
thrombus; 2, subsegmental occlusive thrombus; 3, 
occlusive thrombus throughout the entire segment. 
Each involved limb had a baseline quantitative 
"thrombosis core" based on the number of seg- 
ments involved and the.extent of thrombus in each 
segment. 
Table I lists the extent of lower extremity DVT at 
the time of diagnosis in the study group. Thrombus 
was initially present in 33 of the possible 95 venous 
segments in these 19 limbs (35% of all segments). 
Thrombus was present in the common femoral vein 
in five patients, the superficial femoral vein in 14 
patients, the popliteal vein in 12 patients, the poste- 
rior tibial veins in two patients, the peroneal veins in 
two patients, and the anterior tibial veins in one 
patient. Involvement of two or more venous seg- 
ments was present in 10 patients (53%), and involve- 
ment of three or more segments was present in four 
patients (21%). 
Regression of  lower extremity DVT. Venous 
duplex scanning was repeated at time intervals of I to 
2 weeks, 3 to 6 weeks, 8 to 12 weeks, and 24 to 36 
weeks after the diagnosis of acute DVT. The sum of 
the individual scores for each limb calculated at the 
time of diagnosis (To, as described above) was con- 
sidered to represent 100% for the study group. 
Scores were recalculated ateach interval for all sub- 
jects based on the repeat VDUS, and the individual 
scores were then totaled at each time interval (TN). 
Thrombus regression for the study group at each 
Table II. Residual thrombus and 
fibrinolytic activity at each time interval 
Residual tPA PAI-1 
Interval thrombus activity activity 
(wk) (%) (IU/ml) * p (A U/ml) * 
Diagnosis 100 0.60 _+ 0.07 23.1 -+ 1.8 
1 to 2 95 1.31 -+ 0.26 0.014 20.0 +- 2.7 0.29 
3 to 6 82 1.52 -+ 0.48 0.037 18.4 -+ 2.5 0.21 
8 to 12 60 1.29 -+ 0.26 0.038 22.5 +- 1.5 0.77 
24 to 36 26 0.68 +- 0.15 0.77 22.4 -+ 1.9 0.86 
*All values mean + SEM. 
interval was expressed as a percent residual thrombus 
defined as TN/T o × 100. The course of thrombus 
regression documented by VDUS at each time inter- 
val in the study is listed in Table II. 
Measurement of  endogenous fibrinolytic ac- 
tivity. Measurements of serum tPA and PAI-1 anti- 
gen (total protein) alone do not reliably predict in 
vivo fibrinolytic activity because these assays measure 
both biologically active enzyme and inactive portions 
bound as the tPA/PAI-1 complex. For this reason, 
only serum tPA and PAI-1 activity levels were ana- 
lyzed in this study. Measurements of systemic tPA 
and PAI-1 activities were performed at the time of 
diagnosis of DVT in all patients. Additional assays of 
serum tPA and PAI-1 activities were performed at 
the intervals noted above at the time of repeat 
VDUS. Blood samples were collected in all patients 
using antecubital venipuncture without tourniquet- 
induced venous stasis, and specimens were obtained 
at approximately the same times of day to eliminate 
the known diurnal variations in tPA and PAI-1.1° For 
determination of tPA activity, blood was first col- 
lected into 130 mmol /L  sodium citrate anticoagu- 
lant (9:1 volume). The sample was then immediately 
acidified by addition of 0.5 mmol /L  sodium acetate, 
pH 4.2 (2:1 volume), to prevent the ongoing in vitro 
inactivation of tPA by complex formation with PAI- 
l. It For determination of PAI-1 activity, samples 
were collected into modified Files solution (1 ml 
acid-citrate-dextrose solution, 80 Ixl acetylsalicylic 
acid solution, 10 ~1 prostaglandin El)  to minimize 
in vitro platelet activation (final dilution 1:5)72 Sam- 
ples were maintained at 4 ° C until centrifugation at
10,000g for 20 minutes, and platelet-poor plasma 
was stored at -80 ° C until assays were performed. 
Activity levels of tPA and PAl-1 were assayed using 
an amidolytic method? 3 Assays were performed in 
duplicate, and interassay variability was less than 5%. 
tPA activity was expressed in international units 
( IU/ml) assessed against he Second International 
Standard for tPA from the National Institute for 
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Fig. 1. Mean serum tPA activity level (solid line) for patients in this study at intervals after 
diagnosis of acute lower limb DVT. Thrombus regression observed by VDUS over the same 
intervals (broken line) is expressed as a percentage of initial thrombus burden at the time of 
diagnosis. 
Biological Standards and Control. 14 PM-1 activity 
was expressed in arbitrary units (AU/ml); one arbi- 
trary unit of inhibitor is defined as the amount hat 
inhibits one international unit o f tPA/ml  plasma. 15 
Activity levels of  tPA and PM-1 were combined 
for all patients at each study interval and were ex- 
pressed as mean + SEM for comparison. Changes at 
different ime intervals were compared using Stu- 
dent's t test, and a p value less than 0.05 was used to 
determine statistical significance. This protocol was 
approved by the institutional review board of the 
University of  Maryland, and informed consent was 
obtained from all subjects before their participation. 
RESULTS 
Regression of  lower extremity DVT. The 
thrombus regression scores for the study group at 
each interval are listed in Table II. Lysis of  lower 
extremity DVT began as early as I week after diagno- 
sis. The thrombus regression score decreased to 95% 
at this first time interval and continued to decrease 
almost linearly throughout the study period (Fig. 1). 
At the 3 to 6 week interval the regression score was 
82%; at 8 to 12 weeks 60% of the original thrombus 
load was present; and by the final 24 to 36 week 
period only 26% of the original thrombus burden 
remained. 
An analysis of individual patients revealed that the 
thrombus cores decreased throughout the study pe- 
riod in 15 of the 19 limbs (78.9%). These scores 
increased in three patients, reflecting propagation of 
thrombus observed by VDUS. In two patients prop- 
agation was observed to occur in the first month after 
the diagnosis of  DVT, and propagation was observed 
in one patient during the 8 to 12 week interval 
despite a therapeutic nternational normalized ratio. 
The scores of the patient who died remained un- 
changed over the short period of observation. Com- 
plete resolution of all thrombus by VDUS was noted 
at the end of the study period in 10 of the 18 patients 
who completed follow-up (55.6%). 
Changes in fibrinolytic activity associated 
with DVT regression. Serum tPA activity levels 
measured uring the study period are listed in Table 
II. The mean serum tPA activity level was 0.60 + 
0.07 IU /ml  at diagnosis, which was significantly 
lower than tPA activity for normal age-matched vol- 
unteers in our laboratory (1.80 + 0.23 IU/ml) .  
Serum tPA activity increased to 1.31 - 0.26 IU /ml  
1 to 2 weeks after diagnosis (p = 0.014). The mean 
serum tPA activity levels for the study group re- 
mained significantly elevated at the 3 to 6 week 
interval (1.52 + 0.48 IU /ml ;p  = 0.037) and 8 to 12 
week interval (1.29 + 0.26 IU/ml ;  p = 0.038). The 
activity levels oftPA returned to baseline at 24 to 36 
weeks (0.68 + 0.15 IU/ml ;  p = 0.77). 
The PAI-1 activity levels for the entire study 
period are listed in Table II. The mean PAI-1 activity 
level for the study group at the time of diagnosis of 
lower extremity DVT was 23.0 -+ 1.8 AU/ml.  This 
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Fig. 2. Course of measured tPA activity (solid line) and PM=I activity (broken line) at each 
time interval during the study. Activation of endogenous fibrinolytic activity appeared primarily 
mediated by a significant increase in tPA activity during the study period. 
PAL 1 activity level is significantly higher than base- 
line levels for age-matched normal volunteers in our 
laboratory (12.4 + 1.8 AU/ml)  and (with the asso- 
ciated lower tPA activity levels) is consistent with 
periods of "fibrinolytie shutdown" that have been 
observed in patient groups at higher risk for DVT. 
During the period after diagnosis of acute DVT, 
there were no significant changes in PAL1 activity 
levels in the study group of patients at any of the 
follow-up intervals (Fig. 2). 
Clinical presentation and outcome. No rigor- 
ous objective assessment of patients' clinical condi- 
tion (e.g., limb circumference measurements) was 
performed as part of this analysis, and all observations 
were made on the basis of clinical examination atthe 
time of diagnosis or follow-up testing. As noted 
above, 16 patients ought medical attention with or 
were noted to have significant limb edema at the 
time of diagnosis of acute DVT. The initial mean 
thrombosis score for the 16 patients with lower limb 
edema was 4.5 _+ 0.62 and was not significantly 
different than the asymptomatic patients (4.0 -+ 1.0). 
Over the study period 10 patients had resolution of 
"limb edema, but six patients continued to have sig- 
nificant edema. The final mean thrombosis score for 
patients in whom edema resolved (0.3 -+ 0.21) was 
significantly lower than patients who had residual 
edema (3.0 _+ 1.0; p = 0.05). Baseline serum tPA 
activity levels were identical (p = 0.94) for patients 
who had limb edema compared with those who were 
asymptomatic at the time of DVT diagnosis. How- 
ever, over the study period, the mean tPA levels were 
higher for those patients who had resolution of their 
edema compared with those who remained symp- 
tomatic (p = 0.03). No patient in this study had 
signs of more severe postthrombotic syndrome such 
as hyperpigmentation or ulceration during the pe- 
riod of observation. 
Among the 10 patients who achieved complete 
clot lysis by VDUS at the end of the study period, the 
mean thrombosis core at the time of diagnosis 
(4.1 + 0.75) was not significantly different han 
those patients who were observed to have residual 
thrombus at the completion of the study period 
(4.78 + 0.79; p = 0.70). The mean tPA activity 
levels at the time of diagnosis were identical (p = 
0.85) for those patients who had complete clot lysis 
compared with those who had incomplete lysis. Over 
the study period, tPA activity levels were not ob- 
served to be significantly higher in patients who 
achieved complete clot lysis compared with those 
who had some residual thrombus (p = 0.68). How- 
ever, the three patients who experienced propagation 
of thrombus by VDUS failed to demonstrate any 
increase in tPA activity at the study intervals, whereas 
tPA activity levels were significantly elevated in the 
other patients. 
DISCUSSION 
Recanalization of occluded lower limb venous 
segments after acute DVT was previously considered, 
on the basis of studies that used repeat phlebographic 
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examinations performed months to years after the 
acute event, to be a late reaction} ,2 VDUS has 
greatly expanded our ability to study the natural 
history of DVT because it allows virtually unlimited 
sequential examinations. Studies using VDUS have 
revealed a considerably different pattern of events in 
the natural history of treated DVT than had been 
previously suggested. Killewich et al. 6 reported evi- 
dence of lysis of thrombi and recanalization of ve- 
nous segments een by VDUS as early as the first 
week after diagnosis and observed that residual ve- 
nous occlusion was reduced to 44% by 30 days and to 
14% at 90 days. Thereafter, no significant additional 
lysis was observed in follow-up that continued for 9 
months. Using serial VDUS to study 20 limbs with 
acute DVT, van Ramshorst et al.4 calculated throm- 
bus regression using a method similar to that in the 
present study. Thrombus regression was observed to 
occur in the first 1 to 3 weeks after acute DVT and 
appeared to occur at an almost exponential rate. 
They noted that recanalization occurred mainly in 
the first 6 weeks after diagnosis, but clot resolution 
eventually occurred in 75% of the thrombosed seg- 
ments within 6 months. Caprini et al.5 reported that 
complete resolution had occurred in more than 40% 
of thrombosed venous segments within 3 months 
after the diagnosis of DVT, and lysis had occurred in 
more than 70% of segments within 6 months of 
treatment. The present study would tend to confirm 
the observations summarized above. Some evidence 
of recanalization was evident by VDUS in the first 
weeks after acute DVT. The residual thrombosis 
score for the entire study group was reduced by 40% 
at the 8 to 12 week interval, and the residual throm- 
bosis score rate was 26% at the 24 to 36 week inter- 
val. The rate of clot regression i  our study appeared 
to be a more linear function over time (Fig. 1) rather 
than the exponential rate reported by van Ramshorst 
et al. 4 In addition, recanalization i  our patients did 
not appear elated to the initial burden ofthrombus; 
the mean thrombosis scores at the time of diagnosis 
were not significantly different in patients who had 
complete clot lysis compared with those that had 
some residual thrombus at the end of the study 
period. 
It has generally been presumed that recanaliza- 
tion after acute DVT is a result of a significant en- 
hancement of  endogenous fibrinolytic activity. 
However, few studies to date have reported simulta- 
neous changes in fibrinolytic activity and the mor- 
phologic state of the thromboses. Mirshahi et al}6 in 
1988 mcasured serum levels of fibrin degradation 
products in 47 patients with acute DVT and corn- 
pared these with the anatomic results of repeat phle- 
bograms. A progressive decline in fibrin degradation 
products correlated well with clot resolution, pre- 
sumably the result of ongoing intrinsic lysis that 
eventually exhausted the thrombus ubstrate. It is 
now recognized that a direct assay oftPA and PAI-1 
activities are the most reliable indicators of the state 
of endogenous fibrinolytic activity. Northeast et al. 17 
measured the activity oftPA and urokinase-type las- 
minogen activator (uPA) in thrombi and the adja- 
cent vein walls in a rat model of DVT. They found 
significantly increased tPA and uPA activity in the 
thrombus and reduced tPA and uPA activity in the 
adjacent vein wall. Increased tPA activity was seen at 
48 hours and continued to increase for at least 14 
days. In the present study, significantly increased tPA 
activity levels were observed in the first 1 to 2 weeks 
after acute DVT and persisted throughout the 8 to 
12 week interval. These changes were also accompa- 
nied by regression of DVT seen by direct ultrasound 
imaging. The tPA activity levels returned to baseline 
during the 24 to 36 week interval, by which time 
only 26% of the original quantitative thrombus bur- 
den remained. In this small group of patients, the 
anatomic progress of clot resolution appeared to 
closely parallel changes in the measured tPA activity 
levels. 
Arcelus et al} 8 reported elevated levels of PAI-1 
antigen (total protein) in patients who had incom- 
plete resolution of acute DVT by VDUS (43% of the 
patients in that study). These investigators con- 
cluded that elevated PAI-1 antigen levels might be 
predictive of incomplete resolution of DVT. It is 
now lmown that the measurements oftPA and PAl-1 
antigen alone do not reliably predict in vivo fibrino- 
lyric activity because these assays measure both bio- 
logically active enzyme and inactive portions bound 
as the tPA/PAI-1 complex, la As noted previously, 
only tPA and PAI-1 activity levels were compared in 
the present study. Juhan-Vague t al. 19 associated 
recurrent DVT with a deficiency of tPA release or 
enhanced levels ofPAI-1 as reflected in a response to 
venous occlusion of the arm. Stegnar et al. 2° also 
found that recurrent DVT occurred more frequently 
in patients who had elevated PAI-1 activity after 
venous occlusion. Elevated PAI-1 activity levels have 
been associated with many thrombotic complications 
of atherosclerosis, including myocardial infarction, 21 
stroke, 22 and peripheral arterial occlusive disease. 2a 
No significant changes in serum PAl-1 activity levels 
were found in the study group at any time interval 
during this study. However, there was a decrease in 
the PAI-1 activity levels in the study group that 
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appeared maximum at the 3 to 6 week interval (Fig. 
2), which coincided with the maximum tPA activity 
levels. These combined changes may have served to 
accelerate the process of endogenous clot lysis. 
Recanalizafion of thrombosed venous segments 
does not occur universally after acute DVT. Kille- 
wich et al. 6 observed thrombus propagation by 
VDUS in one third of the cases despite therapeutic 
anticoagulant treatment, and van R}mshorst et al. 4 
observed that thrombus extension occurred in one 
third of cases. 5IQ-upsld et al.7 found that propagation 
occurred in 38% of patients during their initial treat- 
ment of acute lower extremity DVT, and these events 
could not be related to inadequate anticoagulant 
therapy. Propagation of thrombus was observed in 
three patients (15.8%) in the present study; two oc- 
curred within the first month, and one patient was 
observed to have clot extension 3 months after diag- 
nosis. In all patients, propagation was observed e- 
spite apparent therapeutic anticoagulant treatment. 
However, in our patients the serum tPA activity 
levels appeared significantly lower (mean activity, 
0.70 IU/ml)  than other patients at the same time 
intervals (1.29 to 1.52 lU/ml) .  The small number of 
patients who had propagation in this study make 
valid statistical comparison impossible. However, the 
significant increase in tPA activity that was observed 
in other study patients appeared to be related to the 
temporal coursc of clot lysis. Because patients with 
clot propagation were adequately anticoagulated, it 
is possible that a failure of activation of the intrinsic 
fibrinolytic system may have contributed to the ob- 
served clot propagation. 
The measured endpoints of this study did not 
include objectively defined clinical outcomes, but 
several observations are of interest, van Ramshorst et 
al. 4 observed that the likelihood of eventual clot lysis 
appeared irectly related to the initial burden of 
thrombus. In the present study the initial burden of 
thrombus, as reflected by the initial thrombosis 
scores, did not appear to influence the likelihood of 
achieving either complete clot lysis or the resolution 
of symptomatic limb edema. The patients in this 
study did not have the most clinically extensive DVT 
that is seen, because iliofemoral thromboses were 
excluded. Nevertheless, they were a group compara- 
ble with other similar studies. It is evident hat the 
patients who achieve complete clot lysis by VDUS 
would have lower thrombosis scores at the end of the 
study, but patients in this study who had resolution 
of edema also had significantly lower thrombosis 
scores suggesting the potential importance of fi- 
brinolytic activity in the prevention of chronic ve- 
nous dysfunction. Overall, patients who experienced 
resolution of limb edema were observed to have 
significantly higher tPA levels than those with persis- 
tent symptoms. However, the group of patients who 
achieved complete clot lysis did not have significantly 
higher tPA activity levels during the course of the 
study than those whose recanalization was incom- 
plete. It is possible that accelerated endogenous lysis 
of more critical venous segments might prevent 
chronic dysfunction even when overall ysis is incom- 
plete. Similarly, clot propagation in this study ap- 
peared to occur in patients who had a failure of 
activation of the endogenous fibrinolytic system. In 
the past it has been common to assume that propa- 
gation DVT or other thromboembolic complications 
were a result of a "failure of anticoagulation." It is 
possible that this instead represents a failure of the 
endogenous fibrinolytic system in some patients. 
Such a finding might support the more aggressive 
use of exogenous fibrinolytic therapy in some pa- 
tients with acute DVT. 
The patients in this study with acute lower limb 
DVT were observed by serial VDUS to have a pro- 
gressive resolution of thrombosed venous segments 
that began early after diagnosis and continued over a 
period of 6 to 9 months. The overall 74% thrombus 
regression in these patients was accompanied by a 
significant increase in tPA activity levels, indicating 
activation of the endogenous fibrinolytic system. Se- 
rum PAI-1 activity levels did not change during the 
period of observation, which suggests that the enzy- 
matic mechanism of clot lysis was directly related to 
tPA activity. In addition, the', three patients in this 
study who had clot propagation failed to demon- 
strate increased tPA activity. It was also interesting to 
note that patients whose clinical symptoms after 
acute DVT resolved had significantly higher tPA ac- 
tivity levels. Because DVT occurs in approximately 2 
million patients in the United States each year, 24 it is 
unlikely that a study of this size will provide definitive 
answers about this complex process that can be uni- 
versally applied. Further study will be necessary to 
determine whether enhancement of naturally occur- 
ring fibrinolysis by the addition of exogenous fi- 
brinolytic agents might be useful to prevent propaga- 
tion of thrombus, as well as to increase the rate of 
intrinsic thrornbolysis. 
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